MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2023 Dec 23

PMID 38141139

Authors

Nan Wu

Caijie Shen

Jian Wang

Xiaomin Chen

Peng Zhong

Affiliations

Soon will be listed here.

Abstract

Background: Diabetic cardiomyopathy (DCM) pathogenesis is a common complication of diabetes, but effective treatments remain limited. Mitochondrial-derived peptide MOTS-c has shown therapeutic promise in animal models of various heart diseases, but its efficacy in DCM is unknown. This study investigates the effects of MOTS-c treatment in a mouse model of type 1 diabetes-induced DCM.

Methods: Type 1 diabetes (T1DM) was induced in mice by streptozotocin (STZ) injection. After diabetes establishment, the mice were randomly dividend into two groups treated with or without MOTS-c peptide, which was administered subcutaneously by osmotic pump for 12 weeks. At the end of the experiment, cardiac function, histology, and molecular changes were determined.

Results: The results showed that diabetic mice exhibited significant cardiac dysfunction, dilatation, and adverse cardiac remodeling. MOTS-c treatment markedly ameliorated these diabetes-associated myocardial function and structure abnormalities. Additionally, MOTS-c reversed AMPK signaling deactivation and inhibited inflammation in the diabetic heart.

Conclusions: Our data demonstrated a protective effect of MOTS-c against diabetic cardiomyopathy potentially by activating the AMPK pathway and inhibiting inflammation. These findings demonstrate the therapeutic efficacy of MOTS-c for diabetic cardiomyopathy and warrant further investigation into its clinical potential.

Citing Articles

Enhancing Glucose Uptake as a Means to Protect the Heart During Cardiopulmonary Bypass or Ischemia-Reperfusion Injury.

Moran T, Birnbaum Y Cardiovasc Drugs Ther. 2024; 39(1):15-16.

PMID: 39535626 DOI: 10.1007/s10557-024-07648-z.

A Backhanded Approach to Relieving Radial Artery Occlusion.

Reddy R, Blankenship J Cardiovasc Drugs Ther. 2024; 38(6):1089-1090.

PMID: 38916837 DOI: 10.1007/s10557-024-07592-y.

References

Li Y, Ma J, Zhu H, Singh M, Hill D, Greer P . Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes. 2011; 60(11):2985-94. PMC: 3198063. DOI: 10.2337/db10-1333. View

Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B . Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011; 60(6):1770-8. PMC: 3114402. DOI: 10.2337/db10-0351. View

Wu S, Lu Q, Ding Y, Wu Y, Qiu Y, Wang P . Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase α2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes In Vivo. Circulation. 2019; 139(16):1913-1936. PMC: 6465113. DOI: 10.1161/CIRCULATIONAHA.118.033552. View

Yuan J, Wang M, Pan Y, Liang M, Fu Y, Duan Y . The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats. Sci Rep. 2021; 11(1):20077. PMC: 8505603. DOI: 10.1038/s41598-021-99568-3. View

Zhong P, Peng J, Liu T, Ding H . AAV9-Mediated Cardiac CNTF Overexpression Exacerbated Adverse Cardiac Remodeling in Streptozotocin-Induced Type 1 Diabetic Models. Cardiovasc Toxicol. 2021; 22(1):88-96. DOI: 10.1007/s12012-021-09706-6. View

Zhong P, Zeng G, Lei C, Tian G, Ouyang S, Liu F . Ciliary neurotrophic factor overexpression protects the heart against pathological remodelling in angiotensin II-infused mice. Biochem Biophys Res Commun. 2021; 547:15-22. DOI: 10.1016/j.bbrc.2021.01.111. View

Lee C, Zeng J, Drew B, Sallam T, Martin-Montalvo A, Wan J . The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015; 21(3):443-54. PMC: 4350682. DOI: 10.1016/j.cmet.2015.02.009. View

Lee C, Kim K, Cohen P . MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016; 100:182-187. PMC: 5116416. DOI: 10.1016/j.freeradbiomed.2016.05.015. View

Yan Z, Zhu S, Wang H, Wang L, Du T, Ye Z . MOTS-c inhibits Osteolysis in the Mouse Calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation. Pharmacol Res. 2019; 147:104381. DOI: 10.1016/j.phrs.2019.104381. View

10.

Zhai D, Ye Z, Jiang Y, Xu C, Ruan B, Yang Y . MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol Immunol. 2017; 92:151-160. DOI: 10.1016/j.molimm.2017.10.017. View

11.

Li H, Ren K, Jiang T, Zhao G . MOTS-c attenuates endothelial dysfunction via suppressing the MAPK/NF-κB pathway. Int J Cardiol. 2018; 268:40. DOI: 10.1016/j.ijcard.2018.03.031. View

12.

Bairwa S, Parajuli N, Dyck J . The role of AMPK in cardiomyocyte health and survival. Biochim Biophys Acta. 2016; 1862(12):2199-2210. DOI: 10.1016/j.bbadis.2016.07.001. View

13.

Wang X, Wang Y, Antony V, Sun H, Liang G . Metabolism-Associated Molecular Patterns (MAMPs). Trends Endocrinol Metab. 2020; 31(10):712-724. DOI: 10.1016/j.tem.2020.07.001. View

14.

Dasu M, Devaraj S, Zhao L, Hwang D, Jialal I . High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes. 2008; 57(11):3090-8. PMC: 2570406. DOI: 10.2337/db08-0564. View

15.

Ma J, Chadban S, Zhao C, Chen X, Kwan T, Panchapakesan U . TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One. 2014; 9(5):e97985. PMC: 4026484. DOI: 10.1371/journal.pone.0097985. View

16.

Lin M, Yiu W, Wu H, Chan L, Leung J, Au W . Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol. 2011; 23(1):86-102. PMC: 3269929. DOI: 10.1681/ASN.2010111210. View

17.

Zhang Y, Peng T, Zhu H, Zheng X, Zhang X, Jiang N . Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J Transl Med. 2010; 8:133. PMC: 3020152. DOI: 10.1186/1479-5876-8-133. View

18.

Tao A, Song J, Lan T, Xu X, Kvietys P, Kao R . Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice: Role of HMGB1/TLR4/IL-33 axis. Biochim Biophys Acta. 2015; 1852(10 Pt A):2075-85. DOI: 10.1016/j.bbadis.2015.07.015. View

19.

Wu J, Xiao D, Yu K, Shalamu K, He B, Zhang M . The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy. Acta Biochim Biophys Sin (Shanghai). 2023; 55(2):285-294. PMC: 10157545. DOI: 10.3724/abbs.2023006. View

20.

Jiang J, Chang X, Nie Y, Xu L, Yang L, Peng Y . Orally administered MOTS-c analogue ameliorates dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis. Eur J Pharmacol. 2022; 939:175469. DOI: 10.1016/j.ejphar.2022.175469. View